Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge
- PMID: 15298568
- DOI: 10.1111/j.1365-2222.2004.02034.x
Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge
Abstract
Background: Aspirin challenge of aspirin-intolerant asthma (AIA) patients causes a significant increase in leukotriene E4 (LTE4) concentration in urine. However, knowledge on leukotriene B4 (LTB4) generation in patients with AIA is insufficient. Recent research has demonstrated that exogenously administered LTB4 is excreted as glucuronide into the urine in human healthy subjects.
Objective: The purpose of this study is to estimate urinary LTB4 glucuronide (LTBG) concentration in the clinically stable condition in healthy subjects and asthmatic patients and to investigate changes in urinary LTBG concentration in patients with AIA after aspirin challenge.
Methods: A provocation test was performed by intravenous aspirin challenge. After urine was hydrolysed by beta-glucuronidase, the fraction containing LTB4 was purified by high-performance liquid chromatography and LTB4 concentration was quantified by enzyme immunoassay. Urinary LTBG concentration was calculated as the difference between the concentration obtained with hydrolysis and that without hydrolysis.
Results: (1) After hydrolysis, the presence of urinary LTB4 was verified by gas chromatography-mass spectrometry-selected ion monitoring. (2) The urinary LTBG concentration was significantly higher in the asthmatic patients than in the healthy subjects (median, 5.37 pg/mg creatinine [range 1.2-13] vs. 3.32 pg/mg creatinine [range, 0.14-10.5], P = 0.0159). (3) The patients with AIA (n = 7), but not those with aspirin-tolerant asthma (n = 6), showed significant increases in LTBG and LTE4 excretions after aspirin challenge. (4) When the concentrations after aspirin challenge were analysed simultaneously, a significant linear correlation was observed between urinary LTBG concentration and urinary LTE4 concentration in patients with AIA (Spearman's rank correlation test, r = 0.817, P = 0.0003).
Conclusion: LTBG is present in human urine, albeit at a concentration lower than urinary LTE4. In addition to a marked increase in cysteinyl-leukotriene production, aspirin challenge induced LTB4 production in AIA patients.
Similar articles
-
Quantification of leukotriene B4 glucuronide in human urine.Prostaglandins Other Lipid Mediat. 2007 Feb;83(1-2):42-9. doi: 10.1016/j.prostaglandins.2006.09.010. Epub 2006 Dec 5. Prostaglandins Other Lipid Mediat. 2007. PMID: 17259071 Clinical Trial.
-
Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge.Clin Exp Allergy. 2004 Jun;34(6):931-8. doi: 10.1111/j.1365-2222.2004.01968.x. Clin Exp Allergy. 2004. PMID: 15196282
-
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.J Allergy Clin Immunol. 2004 Feb;113(2):277-83. doi: 10.1016/j.jaci.2003.10.068. J Allergy Clin Immunol. 2004. PMID: 14767442
-
Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites.Allergol Int. 2012 Sep;61(3):393-403. doi: 10.2332/allergolint.11-RA-0403. Epub 2012 May 25. Allergol Int. 2012. PMID: 22627848 Review.
-
On the role of PGD2 metabolites as markers of mast cell activation in asthma.Acta Physiol Scand Suppl. 1999 Apr;644:1-74. Acta Physiol Scand Suppl. 1999. PMID: 10352758 Review.
Cited by
-
Mast Cells in Aspirin-Exacerbated Respiratory Disease.Curr Allergy Asthma Rep. 2024 Feb;24(2):73-80. doi: 10.1007/s11882-024-01125-1. Epub 2024 Jan 13. Curr Allergy Asthma Rep. 2024. PMID: 38217825 Review.
-
Hypersensitivity to intravenous succinate corticosteroids in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.Front Allergy. 2023 Nov 10;4:1145809. doi: 10.3389/falgy.2023.1145809. eCollection 2023. Front Allergy. 2023. PMID: 38026126 Free PMC article.
-
Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis.Curr Allergy Asthma Rep. 2022 Dec;22(12):209-229. doi: 10.1007/s11882-022-01049-8. Epub 2022 Nov 14. Curr Allergy Asthma Rep. 2022. PMID: 36374376 Free PMC article. Review.
-
Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.Allergy Asthma Immunol Res. 2022 Mar;14(2):153-167. doi: 10.4168/aair.2022.14.2.153. Allergy Asthma Immunol Res. 2022. PMID: 35255534 Free PMC article. Review.
-
Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2021 Aug;148(2):309-318. doi: 10.1016/j.jaci.2021.06.016. J Allergy Clin Immunol. 2021. PMID: 34364539 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
